US20120277694A1 - Punctal plug with active agent - Google Patents

Punctal plug with active agent Download PDF

Info

Publication number
US20120277694A1
US20120277694A1 US13/533,676 US201213533676A US2012277694A1 US 20120277694 A1 US20120277694 A1 US 20120277694A1 US 201213533676 A US201213533676 A US 201213533676A US 2012277694 A1 US2012277694 A1 US 2012277694A1
Authority
US
United States
Prior art keywords
punctal
punctal plug
plug
stem
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/533,676
Inventor
Steven A. Odrich
Liane C. Glazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mati Therapeutics Inc
Original Assignee
QLT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35096541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120277694(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Assigned to QLT PLUG DELIVERY, INC. reassignment QLT PLUG DELIVERY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GLAZER, LIANE C.
Assigned to QLT PLUG DELIVERY, INC. reassignment QLT PLUG DELIVERY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORSIGHT LABS, LLC
Priority to US13/533,676 priority Critical patent/US20120277694A1/en
Assigned to QLT INC. reassignment QLT INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: 3088922, INC.
Assigned to FORSIGHT NEWCO II, INC. reassignment FORSIGHT NEWCO II, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORSIGHT LABS, LLC
Assigned to 3088922, INC. reassignment 3088922, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: QLT PLUG DELIVERY, INC.
Application filed by QLT Inc filed Critical QLT Inc
Assigned to FORSIGHT LABS, LLC reassignment FORSIGHT LABS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ODRICH, STEVEN A.
Assigned to QLT PLUG DELIVERY, INC. reassignment QLT PLUG DELIVERY, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: FORSIGHT NEWCO II, INC.
Publication of US20120277694A1 publication Critical patent/US20120277694A1/en
Assigned to MATI THERAPEUTICS INC. reassignment MATI THERAPEUTICS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: QLT INC.
Priority to US14/472,844 priority patent/US9463114B2/en
Priority to US15/247,574 priority patent/US20170056322A1/en
Priority to US15/427,578 priority patent/US20170172916A1/en
Priority to US16/360,561 priority patent/US20200138701A9/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Definitions

  • the present invention relates generally to a punctal plug with an active agent.
  • Punctal plugs are known which are made in suitable dimensions and of suitable materials to be removably inserted into the upper and/or lower punctal apertures or punctum of the eye, to block the opening and the canaliculus communicating therewith, to prevent drainage of lacrimal fluid (tears).
  • Such plugs are known to be made of suitable materials, such as polymers, for example polytetrafluorethylene (known by the trademark TEFLON), or hydroxyethylmethacrylate (HEMA), hydrophilic polymer, methyl methacrylate, or silicon, or even of stainless steel or other inert metal material.
  • an active agent such as nicotine or a birth control drug
  • a patch which can be worn against the skin of a subject for transdermally administering the active agent to the subject.
  • an active agent i.e. a medicine or medication
  • transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
  • an ocular implant such as a punctal plug
  • Embodiments of the invention are generally related to the field of medicine, and in particular to a new and useful method and apparatus for administering an active agent, i.e. a medicine or medication, to a subject by transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
  • an active agent i.e. a medicine or medication
  • the active agent or drug is meant for treating the tissues at the walls of the canaliculus, for example, the drug is applied only to inner surfaces of the plug that are adapted to be in contact with or near the tissues of the canaliculus.
  • the presence of tears is highly advantageous as a natural vehicle or carrier for the agent.
  • the active agent or drug is meant for treating the eye itself, the drug is applied only to outer surfaces of the implant or plug that are adapted to be outside the canaliculus.
  • the presence of previously secreted tears or a tear pool is again advantageous as a natural vehicle or carrier for the agent.
  • Any or all surfaces of the implant may carry the active agent there the desire is simply to have the agent enter the subjects blood stream via the tissues in and around the eye.
  • FIG. 1 is a schematic perspective view of an ocular implant in the form of a punctal plug according to the present invention.
  • FIG. 2 is a perspective view of the area around the eye with other embodiments of the invention.
  • FIG. 1 shows a punctal plug generally designated 10 , having a stem 12 for insertion into the punctal aperture 20 of an eye 24 , and along the canaliculus 22 communicating with the aperture.
  • Plug 10 has a large stopper structure 14 connected to the outer end of stem 12 for seating against the aperture 20 and sealing the canaliculus 22 against the flow of tears onto the surface of the eye or eyeball 24 .
  • FIG. 2 illustrates an eye 24 communicating with upper and lower canaliculi 22 a and 22 b , each with their our implant 10 a and 10 b .
  • Implant 10 a is a substantially cylindrical and solid collagen plug that has been inserted into the upper punctum or tear duct 20 a , to block the flow of tears while lower implant 10 b is hollow like a straw for the passage of tears.
  • Implant 10 b includes a tapered shaft or stem 12 a with a flared open end 12 b immobilized at the lower punctum 20 b .
  • a mushroom shaped inner stopper 14 a is formed at the opposite end of shaft 12 a for further setting the location of the implant in the tear duct.
  • One of the embodiments illustrated in FIG. 2 may include a hollow core of the plug and another, e.g. the lower one, may include a hollow core filled with medication.
  • the active agent e.g. a medicine or medication is applied, e.g. in one or more bands of polymer material 16 at the inner end of the stem, or at 18 on the outer end of the stopper 14 in the embodiment of FIG. 1 , or over some or all of the surfaces of the implants of FIG. 2 , or otherwise.
  • Polymer that is absorbent to the agent is preferable so that sufficient agent is present and available for discharge into the surrounding tissues.
  • a porous or absorbent material can alternatively be used to make up the entire plug or implant which can be saturated with the active agent.
  • the hollow implant 10 b of FIG. 2 is also particularly useful in that the active agent can be applied to, or is otherwise available at the inner surface or interior of the implant, and is uniquely structured to pass tears and thus administer the active agent to the tear stream in a fashion that is controlled by the flow of tears which thus act as the carrier for the agent.
  • the hollow implant of the present invention provides a very different drug administering method, scheme and structure.
  • Non-limiting examples of the active agents or medications which are appropriate for use with the invention include, for example only: topical prostaglandin derivatives such as latanoprost, travaprost and bimataprost used for the topical treatment of glaucoma. Also a treatment for corneal infections is appropriate using ciprofloxacin, moxifloxacin or gatifloxacin.
  • Systemic medications useful for this invention are those used for hypertension such as atenolol, nifedipine or hydrochlorothiazide. Any other chronic disease requiring chronic medication could be used.
  • allergic conjunctivitis and rhinitis are also good applications for the invention, e.g. using antihistamine and anti-allergy medication such as olopatadine and cromalyn sodium in or on the implant.
  • active agents are not comprehensive in that many other agents can be used with the present invention.
  • a treatment for dry eye bytopical cyclosporin is particularly interesting for administration by the present invention, but many other active agents can also be administered using the method and apparatus of the invention.
  • the invention is meant to embody all implants or devices which are implanted into the eye-lid canalicular puncta of the naso-lacrimal system with the goal of delivering drug to the eye or to the body.
  • the implant is inserted into either the inferior (lower) or superior (upper) punctum or possibly both.
  • the apparatus is constructed so as to have a drug attached to one or both sides of the implant and an occlusive plug of some inert biocompatible material.
  • the implant could be oriented in the punctal canal to deliver the drug either to the tear lake and thus the eye, or to the nasolacrimal system and thus the body's systemic circulation.
  • the drawings illustrate only three embodiments of the punctal plug or implant delivery system of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)

Abstract

A punctal plug for insertion through a punctal aperture of an eye. The punctal plug includes a stem configured to be inserted into the punctal aperture and along a canaliculus of the eye, a stopper connected to one end of the stem, the stopper configured to seat against the punctal aperture, and a topical prostaglandin. The stem and the stopper are made from a porous or absorbent material, and wherein the material is saturated with the topical prostaglandin.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation application of U.S. patent application Ser. No. 12/604,202, filed Oct. 22, 2009, which is a divisional application of U.S. patent application Ser. No. 10/825,047, filed Apr. 15, 2004, the contents of both of which are incorporated herein by reference in their entireties.
    • FIELD
  • The present invention relates generally to a punctal plug with an active agent.
    • BACKGROUND OF THE INVENTION
  • Punctal plugs are known which are made in suitable dimensions and of suitable materials to be removably inserted into the upper and/or lower punctal apertures or punctum of the eye, to block the opening and the canaliculus communicating therewith, to prevent drainage of lacrimal fluid (tears). Such plugs are known to be made of suitable materials, such as polymers, for example polytetrafluorethylene (known by the trademark TEFLON), or hydroxyethylmethacrylate (HEMA), hydrophilic polymer, methyl methacrylate, or silicon, or even of stainless steel or other inert metal material.
  • It is also known to apply an active agent such as nicotine or a birth control drug, to the inner surface of a patch which can be worn against the skin of a subject for transdermally administering the active agent to the subject.
  • the field of medicine, and in particular to a new and useful method and apparatus for administering an active agent, i.e. a medicine or medication, to a subject by transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
    • SUMMARY OF THE INVENTION
  • It is an aspect of the present invention to provide a method and an apparatus for administering an active agent to a subject by applying the active agent to at least one surface of an ocular implant such as a punctal plug, and installing the implant, e.g. inserting the punctal plug into a punctal aperture of the subject.
  • Embodiments of the invention are generally related to the field of medicine, and in particular to a new and useful method and apparatus for administering an active agent, i.e. a medicine or medication, to a subject by transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
  • If the active agent or drug is meant for treating the tissues at the walls of the canaliculus, for example, the drug is applied only to inner surfaces of the plug that are adapted to be in contact with or near the tissues of the canaliculus. The presence of tears is highly advantageous as a natural vehicle or carrier for the agent.
  • If the active agent or drug is meant for treating the eye itself, the drug is applied only to outer surfaces of the implant or plug that are adapted to be outside the canaliculus. Here the presence of previously secreted tears or a tear pool is again advantageous as a natural vehicle or carrier for the agent.
  • Any or all surfaces of the implant may carry the active agent there the desire is simply to have the agent enter the subjects blood stream via the tissues in and around the eye.
  • The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of this disclosure. For a better understanding of the invention, its operating advantages and specific objects attained by its uses, reference is made to the accompanying drawings and descriptive matter in which preferred embodiments of the invention are illustrated.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the drawings, which are not necessarily drawn to scale, like numerals describe similar components throughout the several views. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in this patent document.
  • FIG. 1 is a schematic perspective view of an ocular implant in the form of a punctal plug according to the present invention; and
  • FIG. 2 is a perspective view of the area around the eye with other embodiments of the invention.
    •  DETAILED DESCRIPTION
  • Referring now to the drawing, FIG. 1 shows a punctal plug generally designated 10, having a stem 12 for insertion into the punctal aperture 20 of an eye 24, and along the canaliculus 22 communicating with the aperture.
  • Plug 10 has a large stopper structure 14 connected to the outer end of stem 12 for seating against the aperture 20 and sealing the canaliculus 22 against the flow of tears onto the surface of the eye or eyeball 24.
  • FIG. 2, where the same of similar numerals are used to designate functionally similar parts, illustrates an eye 24 communicating with upper and lower canaliculi 22 a and 22 b, each with their our implant 10 a and 10 b. Implant 10 a is a substantially cylindrical and solid collagen plug that has been inserted into the upper punctum or tear duct 20 a, to block the flow of tears while lower implant 10 b is hollow like a straw for the passage of tears. Implant 10 b includes a tapered shaft or stem 12 a with a flared open end 12 b immobilized at the lower punctum 20 b. A mushroom shaped inner stopper 14 a is formed at the opposite end of shaft 12 a for further setting the location of the implant in the tear duct.
  • One of the embodiments illustrated in FIG. 2, e.g. the upper implant, may include a hollow core of the plug and another, e.g. the lower one, may include a hollow core filled with medication.
  • The active agent, e.g. a medicine or medication is applied, e.g. in one or more bands of polymer material 16 at the inner end of the stem, or at 18 on the outer end of the stopper 14 in the embodiment of FIG. 1, or over some or all of the surfaces of the implants of FIG. 2, or otherwise. Polymer that is absorbent to the agent is preferable so that sufficient agent is present and available for discharge into the surrounding tissues. A porous or absorbent material can alternatively be used to make up the entire plug or implant which can be saturated with the active agent.
  • The hollow implant 10 b of FIG. 2 is also particularly useful in that the active agent can be applied to, or is otherwise available at the inner surface or interior of the implant, and is uniquely structured to pass tears and thus administer the active agent to the tear stream in a fashion that is controlled by the flow of tears which thus act as the carrier for the agent. Unlike the usual tear stopping punctal plug, the hollow implant of the present invention provides a very different drug administering method, scheme and structure.
  • Non-limiting examples of the active agents or medications which are appropriate for use with the invention include, for example only: topical prostaglandin derivatives such as latanoprost, travaprost and bimataprost used for the topical treatment of glaucoma. Also a treatment for corneal infections is appropriate using ciprofloxacin, moxifloxacin or gatifloxacin. Systemic medications useful for this invention are those used for hypertension such as atenolol, nifedipine or hydrochlorothiazide. Any other chronic disease requiring chronic medication could be used.
  • The treatment of allergic conjunctivitis and rhinitis are also good applications for the invention, e.g. using antihistamine and anti-allergy medication such as olopatadine and cromalyn sodium in or on the implant.
  • The advantage is that there would be no need for chronic pill-taking or drop taking. A once-per 3-6 month visit to the eye doctor would be all that is needed. Also the issue of non-compliance, a major impediment to successful treatment, would by avoided by the invention.
  • This list of active agents is not comprehensive in that many other agents can be used with the present invention. For example, a treatment for dry eye bytopical cyclosporin is particularly interesting for administration by the present invention, but many other active agents can also be administered using the method and apparatus of the invention.
  • The invention is meant to embody all implants or devices which are implanted into the eye-lid canalicular puncta of the naso-lacrimal system with the goal of delivering drug to the eye or to the body.
  • The implant is inserted into either the inferior (lower) or superior (upper) punctum or possibly both. The apparatus is constructed so as to have a drug attached to one or both sides of the implant and an occlusive plug of some inert biocompatible material.
  • Depending on the desired therapy, the implant could be oriented in the punctal canal to deliver the drug either to the tear lake and thus the eye, or to the nasolacrimal system and thus the body's systemic circulation. The drawings illustrate only three embodiments of the punctal plug or implant delivery system of the invention.
  • While a specific embodiment of the invention has been shown and described in detail to illustrate the application of the principles of the invention, it will be understood that the invention may be embodied otherwise without departing from such principles.

Claims (8)

1. A punctal plug for insertion through a punctal aperture of an eye, the punctal plug comprising:
a stem configured to be inserted into the punctal aperture and along a canaliculus of the eye;
a stopper connected to one end of the stem, the stopper configured to seat against the punctal aperture; and
a topical prostaglandin,
wherein the stem and the stopper are made from a porous or absorbent material, and wherein the material is saturated with the topical prostaglandin.
2. The punctal plug of claim 1, wherein the topical prostaglandin is latanoprost.
3. The punctal plug of claim 1, wherein the topical prostaglandin is travaprost.
4. The punctal plug of claim 1, wherein the topical prostaglandin is bimatoprost.
5. A punctal plug for insertion through a punctal aperture of an eye, the punctal plug comprising:
a stem configured to be inserted into the punctal aperture and along a canaliculus of the eye;
a flared end connected to the stem at one end thereof, the flared end configured to sit at the punctal aperture;
an inner stopper connected to the stem at an opposite end from the flared end, the inner stopper configured to set a location of the punctal plug in the canaliculus after the punctal plug has been inserted through the punctal aperture; and
a topical prostaglandin,
wherein the stem, the flared end, and the inner stopper are made from a porous or absorbent material, and wherein the material is saturated with the topical prostaglandin.
6. The punctal plug of claim 5, wherein the topical prostaglandin is latanoprost.
7. The punctal plug of claim 5, wherein the topical prostaglandin is travaprost.
8. The punctal plug of claim 5, wherein the topical prostaglandin is bimatoprost.
US13/533,676 2004-04-15 2012-06-26 Punctal plug with active agent Abandoned US20120277694A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/533,676 US20120277694A1 (en) 2004-04-15 2012-06-26 Punctal plug with active agent
US14/472,844 US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent
US15/247,574 US20170056322A1 (en) 2004-04-15 2016-08-25 Punctal plug with active agent
US15/427,578 US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent
US16/360,561 US20200138701A9 (en) 2004-04-15 2019-03-21 Punctal Plug With Active Agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/825,047 US20050232972A1 (en) 2004-04-15 2004-04-15 Drug delivery via punctal plug
US12/604,202 US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant
US13/533,676 US20120277694A1 (en) 2004-04-15 2012-06-26 Punctal plug with active agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/604,202 Continuation US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/472,844 Continuation US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent

Publications (1)

Publication Number Publication Date
US20120277694A1 true US20120277694A1 (en) 2012-11-01

Family

ID=35096541

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/825,047 Abandoned US20050232972A1 (en) 2004-04-15 2004-04-15 Drug delivery via punctal plug
US12/604,202 Abandoned US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant
US13/533,676 Abandoned US20120277694A1 (en) 2004-04-15 2012-06-26 Punctal plug with active agent
US14/472,844 Expired - Lifetime US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent
US15/247,574 Abandoned US20170056322A1 (en) 2004-04-15 2016-08-25 Punctal plug with active agent
US15/427,578 Abandoned US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent
US16/360,561 Abandoned US20200138701A9 (en) 2004-04-15 2019-03-21 Punctal Plug With Active Agent

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/825,047 Abandoned US20050232972A1 (en) 2004-04-15 2004-04-15 Drug delivery via punctal plug
US12/604,202 Abandoned US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/472,844 Expired - Lifetime US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent
US15/247,574 Abandoned US20170056322A1 (en) 2004-04-15 2016-08-25 Punctal plug with active agent
US15/427,578 Abandoned US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent
US16/360,561 Abandoned US20200138701A9 (en) 2004-04-15 2019-03-21 Punctal Plug With Active Agent

Country Status (1)

Country Link
US (7) US20050232972A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076515B2 (en) 2014-06-24 2018-09-18 Sydnexis, Inc. Ophthalmic Composition
US10813923B1 (en) 2015-04-23 2020-10-27 Sydnexis, Inc. Ophthalmic composition
US11052095B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US11400044B2 (en) 2017-06-16 2022-08-02 AesculaTech, Inc. Thermoresponsive polymers and uses thereof

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20040225250A1 (en) 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
CN101052435B (en) * 2004-07-02 2010-12-08 Qlt塞子传递公司 Treatment medium delivery device
ATE543914T1 (en) * 2005-09-01 2012-02-15 Bristol Myers Squibb Co BIOMARRKERS AND METHODS FOR DETERMINING SENSITIVITY TO VEGFR2 MODULATOR.
US8721656B2 (en) 2006-01-17 2014-05-13 Transcend Medical, Inc. Glaucoma treatment device
CA2637602C (en) 2006-01-17 2014-09-16 Forsight Labs, Llc Drug delivery treatment device
NZ571758A (en) * 2006-03-31 2012-06-29 Quadra Logic Tech Inc A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
CN101505696B (en) * 2006-06-21 2012-11-14 庄臣及庄臣视力保护公司 Punctal plugs for the delivery of active agents
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
CN101505694B (en) * 2006-06-21 2012-02-22 庄臣及庄臣视力保护公司 Punctal plugs for the delivery of active agents
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080057106A1 (en) * 2006-08-29 2008-03-06 Erickson Signe R Low profile bioactive agent delivery device
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
KR20090102810A (en) * 2006-12-26 2009-09-30 큐엘티 플러그 딜리버리, 인코포레이티드 Drug delivery implants for inhibition of optical defects
UY30883A1 (en) 2007-01-31 2008-05-31 Alcon Res PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
WO2009012406A1 (en) 2007-07-17 2009-01-22 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities reference to priority document
AU2008300022A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Lacrimal implant detection
NZ583678A (en) 2007-09-07 2012-03-30 Quadra Logic Tech Inc Silicone matrix drug cores for sustained release of therapeutic agents
ES2525125T3 (en) 2007-09-07 2014-12-17 Mati Therapeutics Inc. Tear implant
EP2254536A2 (en) * 2008-02-18 2010-12-01 QLT Plug Delivery, Inc. Lacrimal implants and related methods
US9132088B2 (en) 2008-04-30 2015-09-15 Mati Therapeutics Inc. Composite lacrimal insert and related methods
EP2276492A2 (en) 2008-05-09 2011-01-26 QLT Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US20090318549A1 (en) * 2008-06-24 2009-12-24 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
ES2640867T3 (en) 2008-06-25 2017-11-07 Novartis Ag Eye implant with ability to change shape
WO2010006053A1 (en) * 2008-07-08 2010-01-14 Qlt Plug Delivery, Inc. Lacrimal implant body including comforting agent
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US20100209477A1 (en) * 2009-01-23 2010-08-19 Qlt Plug Delivery Inc. Sustained release delivery of one or more agents
EP2548538B1 (en) 2009-01-28 2020-04-01 Alcon Inc. Implantation systems for ocular implants with stiffness qualities
CN102395401B (en) 2009-02-12 2015-08-19 因赛普特有限责任公司 Via the drug delivery of water-setting plug
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
EP2398431A4 (en) * 2009-02-23 2014-06-11 Mati Therapeutics Inc Lacrimal implants and related methods
TWI495459B (en) * 2009-03-31 2015-08-11 Johnson & Johnson Vision Care Punctal plugs
US9421127B2 (en) 2009-03-31 2016-08-23 Johnson & Johnson Vision Care, Inc. Punctal plugs
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
US20120245539A1 (en) 2009-11-27 2012-09-27 Qlt Inc. Lacrimal implants including split and insertable drug core
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US9259351B2 (en) 2010-03-29 2016-02-16 Johnson & Johnson Vision Care, Inc. Punctal plugs
US9259352B2 (en) 2010-03-29 2016-02-16 Johnson & Johnson Vision Care, Inc. Punctal plugs
JP2013526572A (en) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド Drug delivery device for the delivery of eye treatments
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
JP6100782B2 (en) * 2011-08-29 2017-03-22 キューエルティー インコーポレイテッド Slow broadcast of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
WO2013049107A2 (en) * 2011-09-27 2013-04-04 The Regents Of The University Of Colorado, A Body Corporate Intraocular encapsulation of oxygenic bacteria
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
EP2844224B1 (en) * 2012-05-03 2018-04-11 Mati Therapeutics Inc. Drug delivery system for treating open angle glaucoma and ocular hypertension
ES2633185T3 (en) 2012-09-17 2017-09-19 Novartis Ag Expandable eye implant devices
WO2014078288A1 (en) 2012-11-14 2014-05-22 Transcend Medical, Inc. Flow promoting ocular implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017062770A1 (en) * 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
CN115120405A (en) 2016-04-20 2022-09-30 多斯医学公司 Delivery device for bioabsorbable ocular drugs
WO2018187693A1 (en) 2017-04-06 2018-10-11 TearDX LLC Ocular devices and methods for the employment thereof
CN108295318B (en) * 2018-01-31 2021-07-06 西安泰科迈医药科技股份有限公司 Temperature-sensitive injectable lacrimal passage suppository and preparation method thereof
CN115066232A (en) 2020-02-06 2022-09-16 视觉治疗股份有限公司 Compositions and methods for treating ocular diseases
DK3884929T3 (en) 2020-03-25 2023-09-25 Ocular Therapeutix Inc EYE IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR
US11331267B2 (en) 2020-09-24 2022-05-17 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device
US20220362055A1 (en) * 2021-05-14 2022-11-17 Glaukos Corporation Materials and methods for punctal plugs

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577319A (en) * 1897-02-16 pfeiffer
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3949750A (en) * 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4660546A (en) * 1984-11-07 1987-04-28 Robert S. Herrick Method for treating for deficiency of tears
US5053030A (en) * 1984-11-07 1991-10-01 Herrick Robert S Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US5049142A (en) * 1984-11-07 1991-09-17 Herrick Robert S Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US5229128A (en) * 1986-06-11 1993-07-20 Haddad Heskel M Drug delivery ophthalmic insert and method of preparing same
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4886488A (en) 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method
US4915684A (en) * 1988-06-21 1990-04-10 Mackeen Donald L Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US5133159A (en) * 1989-01-13 1992-07-28 Nestle S.A. Method for polishing silicone products
US4959048A (en) * 1989-01-17 1990-09-25 Helix Medical, Inc. Lacrimal duct occluder
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5128058A (en) * 1989-05-31 1992-07-07 Hoya Corporation Contact lens cleaner containing a microcapsular polishing agent
IE910450A1 (en) 1990-02-15 1991-08-28 Bausch & Lomb Soft contact lens processing aid
US5163959A (en) 1990-03-29 1992-11-17 Herrick Robert S Method for treating an eye with a canalicular implant having a collapsible flared section
US5171270A (en) 1990-03-29 1992-12-15 Herrick Robert S Canalicular implant having a collapsible flared section and method
US5041081A (en) * 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5116371A (en) * 1990-07-06 1992-05-26 Christensen James M Prosthesis with improved biocompatibility
US5096443A (en) * 1990-11-29 1992-03-17 Siemens Aktiengesellschaft Keyed apparatus for providing ground, power or signal connections
US5283063A (en) * 1992-01-31 1994-02-01 Eagle Vision Punctum plug method and apparatus
US5334137A (en) * 1992-02-21 1994-08-02 Eagle Vision, Inc. Lacrimal fluid control device
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
US5318513A (en) * 1992-09-24 1994-06-07 Leib Martin L Canalicular balloon fixation stent
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5824048A (en) * 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US5417651A (en) * 1993-07-01 1995-05-23 Guena; Nicolas Punctum plug and monocanalicular probe for lacrimal pathology
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
WO1995005161A1 (en) * 1993-08-13 1995-02-23 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US5423777A (en) * 1993-10-27 1995-06-13 Tajiri; Akira Punctum plug
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
JP3486758B2 (en) 1994-06-24 2004-01-13 株式会社高研 Injectable lacrimal canaliculus
US6149684A (en) 1995-06-07 2000-11-21 Herrick; Robert S. Punctum plug having a thin elongated lip and a distal starting tip and method of using
US5723005A (en) * 1995-06-07 1998-03-03 Herrick Family Limited Partnership Punctum plug having a collapsible flared section and method
US5766243A (en) * 1995-08-21 1998-06-16 Oasis Medical, Inc. Abrasive polished canalicular implant
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5741292A (en) * 1995-10-26 1998-04-21 Eagle Vision Punctum dilating and plug inserting instrument with push-button plug release
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5824073A (en) * 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
JPH1033584A (en) 1996-07-26 1998-02-10 M L C:Kk Lacrimal duct insertion appliance
US5993407A (en) 1996-10-25 1999-11-30 Moazed; Kambiz Thomas Transnasal lacrimal insert
JP2001504042A (en) * 1996-11-01 2001-03-27 アルコン ラボラトリーズ，インコーポレイテッド Low-temperature polishing method for soft acrylic articles
US6254562B1 (en) * 1997-02-04 2001-07-03 Alain Fouere Meatus plug for lachrymal canal capable of being screwed
US6041785A (en) * 1997-03-27 2000-03-28 Eaglevision, Inc. Punctum plug
US6016806A (en) 1997-03-27 2000-01-25 Eaglevision, Inc Punctum plug
US6082362A (en) * 1997-03-27 2000-07-04 Eagle Vision, Inc. Punctum plug
US6027470A (en) * 1998-06-10 2000-02-22 Eagle Vision, Inc. Punctum plug and method for inserting the same into the punctual opening
US5961370A (en) * 1997-05-08 1999-10-05 Chiron Vision Corporation Intraocular lens tumbling process using coated beads
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US5830171A (en) 1997-08-12 1998-11-03 Odyssey Medical, Inc. Punctal occluder
US6060439A (en) * 1997-09-29 2000-05-09 Kyzen Corporation Cleaning compositions and methods for cleaning resin and polymeric materials used in manufacture
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
NL1008090C2 (en) 1998-01-22 1999-07-26 Lubberman Bernardus H M Plug for closing a tear duct.
WO1999044553A1 (en) 1998-03-02 1999-09-10 Herrick Family Limited Partnership A punctum plug having a collapsible flared section and method
US6290684B1 (en) * 1998-03-02 2001-09-18 Herrick Family Limited Partnership Punctum plug having a collapsible expanded section and distal tip extending substantially perpendicular thereto and method of inserting same
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6306114B1 (en) * 1998-06-16 2001-10-23 Eagle Vision, Inc. Valved canalicular plug for lacrimal duct occlusion
BR9906772A (en) 1998-07-14 2000-09-26 Alcon Lab Inc Use of 11- (3-dimethylamino-propylidene) -6,11dihydrodibenz [b, e] xepin-2-acetic acid for the manufacture of a medication for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
JP2000070296A (en) * 1998-08-27 2000-03-07 M L C:Kk Intra-lacrimal duct intubation appliance
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6095901A (en) * 1998-12-09 2000-08-01 Alcon Laboratories, Inc. Polishing method for soft acrylic articles
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6234175B1 (en) * 1999-03-23 2001-05-22 Medennium, Inc. Smart ocular plug design and method of insertion for punctal and intracanalicular implants
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6383192B1 (en) * 1999-04-28 2002-05-07 Mlc Limited Company Apparatus for intubation of lacrimal duct
US6428502B1 (en) * 1999-06-25 2002-08-06 Alcon Manufacturing, Ltd. Punctal cannula
US6706275B1 (en) * 1999-09-08 2004-03-16 Matthew W. Camp Scleral plug system
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
US6638239B1 (en) * 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7708711B2 (en) * 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6371122B1 (en) * 2000-06-20 2002-04-16 Robert M. Mandelkorn Gauge/dilator apparatus
US6629533B1 (en) 2000-06-30 2003-10-07 Eagle Vision, Inc. Punctum plug with at least one anchoring arm
EP1305061B1 (en) 2000-08-04 2004-11-03 Medennium, Inc. Ocular plug for punctal and intracanalicular implants
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
JP2004517674A (en) * 2000-12-29 2004-06-17 ボシュ・アンド・ロム・インコーポレイテッド Sustained release drug delivery device
US6964781B2 (en) 2001-01-03 2005-11-15 Bausch & Lomb Incorporated Sustained release drug delivery devices with prefabricated permeable plugs
CA2433528A1 (en) * 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
US20020193441A1 (en) 2001-02-21 2002-12-19 Robertson Stella M. Prostanoid therapies for the treatment of glaucoma
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
CA2442652C (en) 2001-04-07 2011-01-04 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US6605108B2 (en) * 2001-04-13 2003-08-12 Eagle Vision, Inc. Monocanalicular stent
DE60233217D1 (en) * 2001-05-01 2009-09-17 Corium Internat Inc HYDROGEL COMPOSITIONS
US6982090B2 (en) * 2001-05-10 2006-01-03 Gillespie Donald E More easily visualized punctum plug configurations
US7404825B2 (en) * 2001-06-11 2008-07-29 Herrick Ii Robert S Implant capable of forming a differential image in an eye
US20030188879A1 (en) * 2001-08-08 2003-10-09 Easter Mark R. Self-healing cables
FR2829019B3 (en) 2001-08-31 2003-10-31 Alain Fouere LACRYMAL PLUGS AND METHODS OF FITTING THESE DEVICES
BR0212052A (en) 2001-09-11 2004-08-17 Smart Drug Systems Inc Preparation of prolonged release pharmaceutical composition
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US6729939B2 (en) * 2001-12-17 2004-05-04 Bausch & Lomb Incorporated Polishing method for intraocular lens
FR2834446B1 (en) 2002-01-08 2004-02-13 Ioltechnologie Production EXPANDING MEATIC NAIL
US7204995B2 (en) * 2002-01-31 2007-04-17 El-Sherif Dalia M Treatment and control of dry eye by use of biodegradable polymer capsules
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US6866563B2 (en) * 2002-06-27 2005-03-15 Bausch & Lomb Incorporated Apparatus and method for target polishing intraocular lenses
FR2841770B1 (en) 2002-07-05 2004-10-01 Ioltechnologie Production MEATIC NAIL FOR SHUTTERING A LACRYMAL MEAT
FR2844182B1 (en) * 2002-09-11 2004-12-03 Humanoptics Ag CLOSURE PLUG OF A LACRYMAL CANALICLE
US7169163B2 (en) * 2002-09-30 2007-01-30 Bruce Becker Transnasal method and catheter for lacrimal system
JP5583310B2 (en) * 2002-12-20 2014-09-03 チャクシュ・リサーチ・インコーポレーテッド Ophthalmic formulation for prevention and treatment of ocular symptoms
CA2513443A1 (en) * 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US20050283109A1 (en) 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
DE602004028638D1 (en) * 2003-05-02 2010-09-23 Surmodics Inc System for the controlled release of a bioactive agent in the back of the eye
US7204253B2 (en) * 2003-05-22 2007-04-17 Clarity Corporation Punctum plug
US7017580B2 (en) 2003-05-22 2006-03-28 Clarity Corporation Punctum plug system including a punctum plug and passive insertion tool therefor
JP4104137B2 (en) 2003-05-30 2008-06-18 有限会社エム・エル・シー Punctum plug
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
JP4339635B2 (en) 2003-06-12 2009-10-07 有限会社エム・エル・シー Punctum plug
US6994684B2 (en) 2003-06-16 2006-02-07 Alphamed Inc. Punctum plugs having fluid collecting recesses and methods of punctal occlusion
US20040265356A1 (en) 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
JP4280128B2 (en) 2003-08-19 2009-06-17 有限会社エム・エル・シー Punctum plug
JP2005110765A (en) 2003-10-03 2005-04-28 M L C:Kk Lacrimal punctum plug set
JP2005110930A (en) 2003-10-07 2005-04-28 M L C:Kk Lacrimal punctum plug set
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050095269A1 (en) * 2003-11-04 2005-05-05 Ainpour Parviz R. Gel plug for blockage of the canaliculus
US20050220882A1 (en) 2004-03-04 2005-10-06 Wilson Pritchard Materials for medical implants and occlusive devices
US20050197614A1 (en) * 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
JP2004202276A (en) 2004-04-16 2004-07-22 M L C:Kk Intubator implement for reconstructing lacrimal passage
JP2005312835A (en) 2004-04-30 2005-11-10 M L C:Kk Lacrimal passage stent reinforced by thread
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP4644438B2 (en) 2004-05-11 2011-03-02 有限会社エム・エル・シー Brim lacrimal stent
JP4510511B2 (en) 2004-05-18 2010-07-28 有限会社エム・エル・シー A lacrimal stent and lacrimal plug with reinforced collars
CN101052435B (en) * 2004-07-02 2010-12-08 Qlt塞子传递公司 Treatment medium delivery device
US20060020253A1 (en) * 2004-07-26 2006-01-26 Prescott Anthony D Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
DE102004040736B4 (en) * 2004-08-23 2007-01-11 Sanofi-Aventis Deutschland Gmbh Process for the preparation of Diarylcycloalkylderivaten
WO2006031658A2 (en) 2004-09-10 2006-03-23 Allergan, Inc. Therapeutic lacrimal canalicular inserts and related methods
US20060074370A1 (en) * 2004-09-24 2006-04-06 Medennium, Inc. Ocular occluder and method of insertion
MX2007006214A (en) 2004-11-24 2008-04-16 Therakine Ltd An implant for intraocular drug delivery.
US20060233858A1 (en) 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US7862532B2 (en) * 2005-10-07 2011-01-04 Delta Life Sciences, Inc. Punctum plugs having insertion guides and strengthening beams
US20070132125A1 (en) * 2005-12-08 2007-06-14 Bausch & Lomb Incorporated Use of a super-cooled fluid in lens processing
JP4078371B2 (en) 2006-01-27 2008-04-23 章弘 小栗 Punctum plug
NZ571758A (en) * 2006-03-31 2012-06-29 Quadra Logic Tech Inc A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
US9474645B2 (en) 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
FR2908042B1 (en) 2006-11-08 2009-06-05 Bruno Fayet MONOCANALICULONASAL AND / OR MONOCANALICULAR INTUBATION ASSEMBLY, IN PARTICULAR FOR LACRYMONASAL IMPERFORATION.
UY30883A1 (en) 2007-01-31 2008-05-31 Alcon Res PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
CN101969897A (en) * 2007-09-07 2011-02-09 Qlt栓塞输送公司 Insertion and extraction tools for lacrimal implants
NZ583678A (en) 2007-09-07 2012-03-30 Quadra Logic Tech Inc Silicone matrix drug cores for sustained release of therapeutic agents
ES2525125T3 (en) * 2007-09-07 2014-12-17 Mati Therapeutics Inc. Tear implant

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11596625B2 (en) 2014-06-24 2023-03-07 Sydnexis, Inc. Ophthalmic composition
US11883390B2 (en) 2014-06-24 2024-01-30 Sydnexis, Inc. Ophthalmic composition
US11896588B2 (en) 2014-06-24 2024-02-13 Sydnexis, Inc. Ophthalmic composition
US10842787B2 (en) 2014-06-24 2020-11-24 Sydnexis, Inc. Ophthalmic composition
US11890277B2 (en) 2014-06-24 2024-02-06 Sydnexis, Inc. Ophthalmic composition
US10201534B2 (en) 2014-06-24 2019-02-12 Sydnexis, Inc. Ophthalmic composition
US10076515B2 (en) 2014-06-24 2018-09-18 Sydnexis, Inc. Ophthalmic Composition
US10864208B2 (en) 2014-06-24 2020-12-15 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US10813923B1 (en) 2015-04-23 2020-10-27 Sydnexis, Inc. Ophthalmic composition
US10953002B2 (en) 2015-04-23 2021-03-23 Sydnexis, Inc. Ophthalmic composition
US10940145B2 (en) 2015-04-23 2021-03-09 Sydnexis, Inc. Ophthalmic composition
US10888557B2 (en) 2015-04-23 2021-01-12 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US11052095B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US12070466B2 (en) 2015-05-29 2024-08-27 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US11400044B2 (en) 2017-06-16 2022-08-02 AesculaTech, Inc. Thermoresponsive polymers and uses thereof

Also Published As

Publication number Publication date
US20050232972A1 (en) 2005-10-20
US9463114B2 (en) 2016-10-11
US20100040670A1 (en) 2010-02-18
US20170172916A1 (en) 2017-06-22
US20150132358A1 (en) 2015-05-14
US20190216727A1 (en) 2019-07-18
US20170056322A1 (en) 2017-03-02
US20200138701A9 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
US9463114B2 (en) Punctal plug with active agent
US7943162B2 (en) Drug delivery device
US6808719B2 (en) Drug delivery device
US6986900B2 (en) Ophthalmic drug delivery device
US8469934B2 (en) Pulsatile peri-corneal drug delivery device
JP5896966B2 (en) Reservoir device for intraocular drug delivery
US7094226B2 (en) Ophthalmic drug delivery device
US20060039952A1 (en) Ophthalmic drug delivery device
WO2000062760A1 (en) Ophthalmic insert and method for sustained release of medication to the eye
AU1081201A (en) Ophthalmic drug delivery device

Legal Events

Date Code Title Description
AS Assignment

Owner name: QLT INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:3088922, INC.;REEL/FRAME:028447/0274

Effective date: 20110215

Owner name: QLT PLUG DELIVERY, INC., DELAWARE

Free format text: CHANGE OF NAME;ASSIGNOR:FORSIGHT NEWCO II, INC.;REEL/FRAME:028447/0092

Effective date: 20071018

Owner name: FORSIGHT NEWCO II, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORSIGHT LABS, LLC;REEL/FRAME:028447/0026

Effective date: 20071018

Owner name: QLT PLUG DELIVERY, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLAZER, LIANE C.;REEL/FRAME:028447/0176

Effective date: 20080207

Owner name: 3088922, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QLT PLUG DELIVERY, INC.;REEL/FRAME:028447/0235

Effective date: 20101215

Owner name: FORSIGHT LABS, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ODRICH, STEVEN A.;REEL/FRAME:028446/0995

Effective date: 20061124

Owner name: QLT PLUG DELIVERY, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORSIGHT LABS, LLC;REEL/FRAME:028447/0141

Effective date: 20080201

AS Assignment

Owner name: MATI THERAPEUTICS INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QLT INC.;REEL/FRAME:030266/0677

Effective date: 20130413

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION